Action Biogen - 1BIIB

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

128,60

Prix Achat

128,55

Prix Vente

129,95

Volume échangé

129,85 Fourchette du Jour 130,25

125,25 Plage de 52 semaines 220,70

Cap du marché

18,824B

Clôture Veille

129,35

Ouverture

129,85

Dernière Transaction

129.95

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

146 374 937

Rendement du Dividende

Ratio Cours sur Bénéfices

12,55

Bénéfice par action (BPA)

11,15

Chiffre d'affairess

9,68B

Bénéfice net

1,63B

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.biogen.com

Siège social

Wilmington, Delaware, USA

Fondé

Biogen Inc est coté dans le secteur Biological Pds,ex Diagnstics de la Italian Stock Exchange avec le ticker 1BIIB. Le dernier cours de clôture d'Biogen était de 129,35 €. Au cours de la dernière année, les actions de Biogen ont été négociées dans une fourchette de prix de 125,25 € à 220,70 €.

Biogen compte actuellement 146 374 937 actions en circulation. La capitalisation boursière d'Biogen est de 18,93 € milliard. Biogen a un ratio cours/bénéfice (ratio PE) de 12.55.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-7	-5.16224188791	135.6	145.05	129.85	59	139.42553191	DE
4	0.3	0.233826968044	128.3	145.05	127.2	76	135.57990552	DE
12	-13.4	-9.43661971831	142	149.4	125.25	76	138.43914501	DE
26	-51.25	-28.4959688629	179.85	182	125.25	60	146.73989013	DE
52	-74.6	-36.7125984252	203.2	220.7	125.25	49	161.75718026	DE
156	-87	-40.3525046382	215.6	244.6	125.25	44	166.92525113	DE
260	-87	-40.3525046382	215.6	244.6	125.25	44	166.92525113	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 128,60 €

How many Biogen shares are in issue?

Biogen has 146 374 937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 18,93B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 125,25 € to 220,70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12,55

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2,12

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9,68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1,63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
1INTCIntel Corp	21,96 € (15,63%)	172,7k
ARNAlerion Clean Power S.P.A.	13,94 € (13,70%)	144,19k
FPEFope	32,00 € (12,68%)	23k
MPTImpianti SpA	0,785 € (12,14%)	528k
FIREBifire spa	2,78 € (12,10%)	37,5k
AURNB Aurora SA SicafRaif	10,00 € (-26,50%)	17,12k
GTGT Talent Group SpA	0,164 € (-18,00%)	375
NTWNetweek SpA	0,033 € (-14,06%)	581,19k
1IRBTIrobot Corp Dl 01	3,45 € (-14,03%)	5,48k
FDAFidia	0,0082 € (-12,77%)	20,17M
TITTelecom Italia SpA	0,2786 € (1,75%)	300,01M
ISPIntesa Sanpaolo Spa	4,711 € (-1,22%)	57,06M
SPMSaipem Spa	2,013 € (-3,31%)	42,58M
TITRTelecom Italia	0,3157 € (1,19%)	22,23M
ENELEnel Spa	6,994 € (0,37%)	22,16M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen Inc (1BIIB)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biogen Inc

1BIIB Dernières nouvelles

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biogen Inc (1BIIB) Cours

Biogen Inc (1BIIB)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biogen Inc

1BIIB Dernières nouvelles

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités